ArticleJournal of neural transmission (Vienna, Austria : 1996)2026
Arginine-vasopressin systems in autistic phenotype schizophrenia: effect of a genetic variant of AVPR1a and AVPR1b.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Much attention has been devoted to exploring the similarities between schizophrenia and autism spectrum disorder (ASD). Autistic traits in schizophrenia have recently been assessed using the Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS). Although studies on arginine-vasopressin (AVP) systems have focused on the etiology of ASD, there are no reports regarding AVP systems and autistic traits in schizophrenia. This study aimed to assess autistic traits in schizophrenia using the PAUSS and examine their associations with the PAUSS and AVP-related biological measures. This is a cross-sectional study. We recruited patients with schizophrenia (n = 80) and healthy controls (HCs; n = 27). Patients with schizophrenia were classified as having either an autistic phenotype schizophrenia (AU) or a non-autistic phenotype (NAU). All patients with schizophrenia underwent clinical assessments focusing on symptom severity, autistic traits, neurocognition, and social cognition. HCs were examined for neurocognition and social cognition. We also evaluated AVP-related biomarkers, including serum AVP levels, single-nucleotide polymorphisms, and promoter-region microsatellites. The AU group showed worse symptom severity and social cognition than the NAU group. The T allele of rs28632197 in the AVP receptor (AVPR)1b was associated with more severe autistic traits in patients with schizophrenia, while the short allele of RS1 in AVPR1a was associated with less severe autistic traits. Our results suggest that autistic traits in schizophrenia are linked to more severe symptoms and poorer social cognition and that AVP system dysfunction may contribute to their etiology. Clinicians should carefully evaluate autistic traits.
Indexed as
Identifiers
42047756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.